ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1033

Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort

Tien-Ming Chan, Chang Gung Memorial Hospital, Taoyuan, Taiwan (Republic of China)

Meeting: ACR Convergence 2025

Keywords: Autoantibody(ies), Epidemiology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1007–1037) Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: ANA prevalence and patterns vary in RA. Using ICAP nomenclature, this study aimed to determine the prevalence of RA across different ANA patterns and the distribution of these patterns in RA patients within a large Taiwanese cohort.

Methods: This cross-sectional study used the Chang Gung Research Database (2019-2021). Patients undergoing ANA IIF testing (HEp-2 substrate, ≥1:100 positive) were included. Patients with inconsistent/mixed patterns were excluded from pure pattern analysis. RA diagnosis used ICD codes confirmed by rheumatologists. RA prevalence and odds ratios (ORs) were calculated for each ANA pattern (AC-1 to AC-29) versus ANA-negative (AC-0). ANA pattern/titer distributions were compared between RA and non-RA cohorts.

Results: Among 35,763 patients with single, consistent ANA patterns, 4,612 (12.9%) were ANA-positive. RA prevalence in the AC-0 group was 4.62%. Significantly higher RA prevalence occurred with AC-2 (Dense fine speckled, 11.92%, OR 2.80), AC-1 (Homogeneous, 10.02%, OR 2.30), AC-4 (Fine speckled, 9.85%, OR 2.26), and AC-5 (Coarse speckled, 8.95%, OR 2.03) patterns (all p< 0.001). In the RA cohort (n=1,860 with pure patterns), ANA positivity was 22.69% (vs. 12.38% in non-RA, p< 0.0001), with higher titers. The most frequent patterns in ANA-positive RA were Speckled (AC-4/AC-5, 8.66%), Dense fine speckled (AC-2, 4.03%), Homogeneous (AC-1, 3.01%), and Centromere (AC-3, 2.26%).

Conclusion: Specific ANA patterns (AC-1, AC-2, AC-4, AC-5) are significantly associated with increased RA prevalence in this Taiwanese cohort. RA patients show higher ANA positivity and titers, favoring speckled, dense fine speckled, and homogeneous patterns. Detailed ICAP pattern reporting is clinically relevant for RA assessment.

Supporting image 1Table 1. Prevalence of Rheumatoid Arthritis Across Different Pure ANA Staining Patterns Compared to ANA-negative Patients

Supporting image 2Figure 1. Flowchart illustrating the distribution of ANA patterns (AC-1 to AC-29) among rheumatoid arthritis patients tested at Chang Gung Memorial Hospital (2019–2021)

Supporting image 3Figure 2. Distribution of Pure-Single ANA Patterns in ANA-Positive Rheumatoid Arthritis Patients


Disclosures: T. Chan: None.

To cite this abstract in AMA style:

Chan T. Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/rethinking-ana-in-rheumatoid-arthritis-icap-pattern-insights-from-a-large-scale-taiwanese-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rethinking-ana-in-rheumatoid-arthritis-icap-pattern-insights-from-a-large-scale-taiwanese-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology